|
| View:
Latest News | Top Stories |
|
| 1.
|
Amgen's osteoporosis drug meets study goal
-
AP
-
Fri 5:01 pm ET
Biotechnology company Amgen Inc. said Friday its osteoporosis drug reduced the incidence of fractured vertebrae in postmenopausal women, meeting a late-stage study goal and driving shares higher in after-hours trading.
|
|
| 2.
|
Insmed to Host Second Quarter 2008 Conference Call
-
PR Newswire
-
Fri 8:15 am ET
Insmed Inc. , a developer of follow-on biologics and biopharmaceuticals, today announced that it will host a conference call on Friday, August 8th at 8:30 AM ET, to discuss its results for the second quarter 2008.
|
|
| 3.
|
Osiris Therapeutics Closes Osteocel Transaction Worth up to $137 Million
-
Business Wire
-
Thu 4:38 pm ET
COLUMBIA, Md.----Osiris Therapeutics, Inc. today announced that it has closed its definitive agreement with NuVasive, Inc. for the purchase of the Osteocel business in a transaction worth up to $137 million.
|
|
| 4.
|
Sector Snap: Biotech outpaces the market
-
AP
-
Thu Jul 24
Wall Street has so far dealt with a mixed second-quarter report card for biotechnology companies, but shares continue outpacing the broader market on a mix of positive sales results and a bright outlook for buyout potential within the sector.
|
|
| 5.
|
Biotech stages a "strong comeback" Part I
-
SmallCapInvestor.com
-
Thu Jul 24
Unlike previous downturns, health care and biotech have underperformed this year relative to previous bust cycles. However, this near-term trend looks as though it may be reversing.
|
|
| 6.
|
Check on China: 3SBio Inc.
-
SmallCapInvestor.com
-
Thu Jul 24
One Chinese company capitalizing on the spike in health-care spending while avoiding drug safety problems is 3SBio Inc. , a biopharmaceutical products company that specializes in...
|
|
| 7.
|
Medarex Receives Milestone Payment for Acceptance of Investigational New Drug Application
-
PR Newswire
-
Wed Jul 23
Medarex, Inc. today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the acceptance of an Investigational New Drug Application to the U.S.
|
|
| 8.
|
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
-
PR Newswire
-
Wed Jul 23
Dendreon Corporation today announced that it expects the Independent Data Monitoring Committee to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT clinical trial of PROVENGEŽ .
|
|
| 9.
|
AOB Enjoys Solid Growth from TCM
-
Zacks.com
-
Mon Jul 21
We maintain our Buy rating on American Oriental Bioengineering Inc. as first-quarter financials were strong.
|
|
| 10.
|
Biopure plans blood substitute study
-
AP
-
Mon Jul 7
Drug developer Biopure Corp. said Monday it will file a study plan for its experimental blood substitute Hemopure with the Food and Drug Administration, months after the agency was criticized for its lack of action on potential safety risks associated with synthetic blood products.
|
|
